Genzyme Develops Beijing R&D Center

Published May 2008

BEIJING -

Genzyme Corp. is planning to construct a new 200,000-sf R&D center in the Zhongguancun Life Science Park in Beijing. The $90 million facility will accommodate research and development in areas including orthopedics, transplant and immune disease, oncology, endocrinology, and cardiovascular disease, as well as laboratory-scale operations for the MACI(R) (matrix-induced autologous chondrocyte implantation) cell therapy and polyclonal antibody operations. LEED certification will be sought for the project, which will include a living roof, a solar thermal system, use of natural light, and low flow water fixtures. The architect is RMJM Hillier with MW Zander as project engineer. Occupancy is slated for 2010. Copyright 2008 Tradeline Inc.
All Rights Reserved
ISSN: 1096-4894